1
|
Lacan C, Lambert J, Forcade E, Robin M, Chevallier P, Loron S, Bulabois CÉ, Orvain C, Ceballos P, Daguindau E, Charbonnier A, Chalandon Y, Bernard M, Simand C, Rubio MT, Turlure P, Maertens J, Huynh A, Loschi M, Bay JO, Guillerm G, Alani M, Castilla-Llorente C, Poiré X, Chantepie S, Maillard N, Beguin Y, Marçais A, Cornillon J, Malfuson JV, Maury S, Meuleman N, Villate A, Bekadja MA, Walter-Petrich A, Jacque N, Srour M, Devillier R, Nguyen S. Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry. J Hematol Oncol 2024; 17:2. [PMID: 38185663 PMCID: PMC10773006 DOI: 10.1186/s13045-023-01515-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Accepted: 11/25/2023] [Indexed: 01/09/2024] Open
Abstract
The use of peripheral blood (PB) or bone marrow (BM) stem cells graft in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis remains controversial. Moreover, the value of adding anti-thymoglobulin (ATG) to PTCy is unknown. A total of 1344 adult patients received an unmanipulated haploidentical transplant at 37 centers from 2012 to 2019 for hematologic malignancy. We compared the outcomes of patients according to the type of graft, using a propensity score analysis. In total population, grade II-IV and III-IV acute GVHD (aGVHD) were lower with BM than with PB. Grade III-IV aGVHD was lower with BM than with PB + ATG. All outcomes were similar in PB and PB + ATG groups. Then, in total population, adding ATG does not benefit the procedure. In acute leukemia, myelodysplastic syndrome and myeloproliferative syndrome (AL-MDS-MPS) subgroup receiving non-myeloablative conditioning, risk of relapse was twice greater with BM than with PB (51 vs. 22%, respectively). Conversely, risk of aGVHD was greater with PB (38% for aGVHD II-IV; 16% for aGVHD III-IV) than with BM (28% for aGVHD II-IV; 8% for aGVHD III-IV). In this subgroup with intensified conditioning regimen, risk of relapse became similar with PB and BM but risk of aGVHD III-IV remained higher with PB than with BM graft (HR = 2.0; range [1.17-3.43], p = 0.012).
Collapse
Affiliation(s)
- Claire Lacan
- Clinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, APHP, 47-83 Bd de l'Hôpital, 75013, Paris, France
| | - Jérôme Lambert
- Institut national de la santé et de la recherche médicale (INSERM), U1153 CRESS, Paris, France
- Service de Biostatistique et Information Médicale, Hôpital Saint Louis, APHP, Paris, France
| | - Edouard Forcade
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Marie Robin
- Clinical Hematology Unit, Hôpital Saint Louis, APHP, Paris, France
| | - Patrice Chevallier
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Sandrine Loron
- Clinical Hematology Unit, Hôpital Lyon Sud, HCL, Lyon, France
| | - Claude-Éric Bulabois
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Grenoble, Grenoble, France
| | - Corentin Orvain
- Clinical Hematology Unit, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - Patrice Ceballos
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Etienne Daguindau
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Besançon, Besançon, France
| | - Amandine Charbonnier
- Clinical Hematology Unit, Centre Hospitalier Universitaire d'Amiens, Amiens, France
| | - Yves Chalandon
- Clinical Hematology Unit, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - Marc Bernard
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - Célestine Simand
- Clinical Hematology Unit, Institut de Cancérologie Strasbourg Europe, Strasbourg, France
| | - Marie-Thérèse Rubio
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Nancy, Nancy, France
| | - Pascal Turlure
- Clinical Hematology Unit, Centre Hospitalier Universitaire Dupuytren, Limoges, France
| | | | - Anne Huynh
- Clinical Hematology Unit, Oncopôle, Toulouse, France
| | - Michael Loschi
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Jacques-Olivier Bay
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
| | - Gaëlle Guillerm
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Brest, Brest, France
| | - Mustafa Alani
- Clinical Hematology Unit, Centre Henri Becquerel, Rouen, France
| | | | - Xavier Poiré
- Clinical Hematology Unit, Clinique Universitaire Saint Luc, Leuven, Belgium
| | - Sylvain Chantepie
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Caen, Caen, France
| | - Natacha Maillard
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Yves Beguin
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Liège and University of Liège, Liège, Belgium
| | - Ambroise Marçais
- Clinical Hematology Unit, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Jérôme Cornillon
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Saint Etienne, Saint Etienne, France
| | - Jean-Valère Malfuson
- Clinical Hematology Unit, Hôpitaux d'Instruction des Armées Percy, Clamart, France
| | - Sébastien Maury
- Clinical Hematology Unit, Hôpital Henri Mondor, APHP, Créteil, France
| | | | - Alban Villate
- Clinical Hematology Unit, Hôpital Bretonneau, Tours, France
| | - Mohammed-Amine Bekadja
- Clinical Hematology Unit, Clinic of Hematology and Cell Therapy, EHU 1St November, Oran, Algeria
| | - Anouk Walter-Petrich
- Institut national de la santé et de la recherche médicale (INSERM), U1153 CRESS, Paris, France
- Service de Biostatistique et Information Médicale, Hôpital Saint Louis, APHP, Paris, France
| | - Nathalie Jacque
- Clinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, APHP, 47-83 Bd de l'Hôpital, 75013, Paris, France
| | - Micha Srour
- Clinical Hematology Unit, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Raynier Devillier
- Clinical Hematology Unit, Institut Paoli Calmette, Marseille, France
| | - Stéphanie Nguyen
- Clinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, APHP, 47-83 Bd de l'Hôpital, 75013, Paris, France.
| |
Collapse
|
2
|
Bekadja MA, Mansour B, Ouldjeriouat H, Entasoltan B, Bouchama S, Charef L, Amani K, Hakiki N, Bouamama F, Osmani S, Brahimi M, Arabi A, Bouhass R, Yafour N. First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients. Transfus Apher Sci 2021; 60:103070. [PMID: 33612450 DOI: 10.1016/j.transci.2021.103070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Revised: 12/24/2020] [Accepted: 01/20/2021] [Indexed: 11/18/2022]
Abstract
Mobilization failure in patients is a major therapeutic concern which makes subsequent ASCT impossible. A new growth factor called Plerixafor (Mozobil®) developed by the pharmaceutical industry (Sanofi-aventis, France), is a chemoreceptor antagonist, CXCR4 type, which disrupts the interaction of SDFI and CXCR4, thereby enhancing the effect of G-CSF mobilization and is especially indicated for mobilization failure. Currently, there is a generic of plerixafor developed by the pharmaceutical industry (Hetero Drugs Ltd, India). The brand name of this medicine is Mozifor®. The objective of this study was to evaluate if generic plerixafor has the same efficacy and safety as originator plerixafor when used with G-CSF in the mobilization of PBSCs for autologous ASCT in multiple myeloma (MM) and lymphoma failure patients. The 32 patients received plerixafor were divided in two groups. The first group concerns the 11 consecutive patients prospectively received generic plerixafor (Mozifor®) in the period between January to July 2020. These were compared with a retrospective control cohort (second group n = 21) who had been treated between 2009 and 2019 with originator plerixafor (Mozobil®). For the Mozifor® group, the mean CD34+ was 4.54x106/kg(1.56-6.79), the median time to achieve an absolute neutrophil count >0.5 G/L was 13 days (range: 8-21). The median time to self-sustained platelet count >20 G/L was 15 days (range: 8-24). For the Mozobil® group, the mean CD34+ was 3.1x106/kg (0.56-8.91) (p=0.86), the median time to achieve an absolute neutrophil count >0.5 G/L was 10 days (range 7-23). The median time to self-sustained platelet count >20 G/L was 13 days (range: 7-29). Our study showed that the generic of plerixafor was practically identical to that of the originator (Mozobil®) with no significant difference (p = 0.52). This study demonstrates the safety and feasibility of mobilization PBSC with generic plerixafor in ASCT in MM and lymphoma. Although these outcomes are encouraging, prospective comparison with other traditional auto-HCT regimens used for patients with MM and lymphoma is warranted.
Collapse
Affiliation(s)
- M A Bekadja
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria.
| | - B Mansour
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria
| | - H Ouldjeriouat
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria
| | - B Entasoltan
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria
| | - S Bouchama
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria
| | - L Charef
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria
| | - K Amani
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria
| | - N Hakiki
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria
| | - F Bouamama
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria
| | - S Osmani
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria
| | - M Brahimi
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria
| | - A Arabi
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria
| | - R Bouhass
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria
| | - N Yafour
- Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria
| |
Collapse
|
4
|
Bekadja MA, Bouhass R, Osmani S, Brahimi M, Talhi S, Yafour N, Arabi A. Plerixafor in the treatment of progenitor cell mobilization failure: First experience in Algeria. Hematol Oncol Stem Cell Ther 2015; 8:93-4. [PMID: 25571787 DOI: 10.1016/j.hemonc.2014.11.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2014] [Revised: 10/12/2014] [Accepted: 11/22/2014] [Indexed: 11/28/2022] Open
Affiliation(s)
- M A Bekadja
- Hematology and Cell Therapy Department, Etablissement Hospitalier et Universitaire 1er Novembre, University of Oran, Algeria.
| | - R Bouhass
- Hematology and Cell Therapy Department, Etablissement Hospitalier et Universitaire 1er Novembre, University of Oran, Algeria
| | - S Osmani
- Hematology and Cell Therapy Department, Etablissement Hospitalier et Universitaire 1er Novembre, University of Oran, Algeria
| | - M Brahimi
- Hematology and Cell Therapy Department, Etablissement Hospitalier et Universitaire 1er Novembre, University of Oran, Algeria
| | - S Talhi
- Hematology and Cell Therapy Department, Etablissement Hospitalier et Universitaire 1er Novembre, University of Oran, Algeria
| | - N Yafour
- Hematology and Cell Therapy Department, Etablissement Hospitalier et Universitaire 1er Novembre, University of Oran, Algeria
| | - A Arabi
- Hematology and Cell Therapy Department, Etablissement Hospitalier et Universitaire 1er Novembre, University of Oran, Algeria
| |
Collapse
|